| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 941 | 2018 |
| Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial IN van Schaik, V Bril, N van Geloven, HP Hartung, RA Lewis, G Sobue, ... The Lancet Neurology 17 (1), 35-46, 2018 | 259 | 2018 |
| Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study P O'Connor, G Comi, MS Freedman, AE Miller, L Kappos, JP Bouchard, ... Neurology 86 (10), 920-930, 2016 | 135 | 2016 |
| Global impact of COVID-19 on stroke care and IV thrombolysis RG Nogueira, MM Qureshi, M Abdalkader, SO Martins, H Yamagami, ... Neurology 96 (23), e2824-e2838, 2021 | 123 | 2021 |
| Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial DS Reich, DL Arnold, P Vermersch, A Bar-Or, RJ Fox, A Matta, T Turner, ... The Lancet Neurology 20 (9), 729-738, 2021 | 110 | 2021 |
| Personality as a predictor of coping efforts in patients with multiple sclerosis T Rätsep, T Kallasmaa, A Pulver, K Gross-Paju Multiple Sclerosis Journal 6 (6), 397-402, 2000 | 108 | 2000 |
| A questionnaire assessment of unmet needs for rehabilitation services and resources for people with multiple sclerosis: results of a pilot survey in five European countries P Kersten, DL McLellan, K Gross-Paju, N Grigoriadis, R Bencivenga, ... Clinical Rehabilitation 14 (1), 42-49, 2000 | 88 | 2000 |
| Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ... Neurology 84 (11), 1145-1152, 2015 | 81 | 2015 |
| Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction L Vahter, I Zopp, M Kreegipuu, P Kool, T Talvik, K Gross-Paju Multiple Sclerosis Journal 15 (3), 379-384, 2009 | 69 | 2009 |
| Changes in blood B cell-activating factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome K Kannel, K Alnek, L Vahter, K Gross-Paju, R Uibo, KV Kisand PLoS One 10 (11), e0143393, 2015 | 63 | 2015 |
| Subjective complaints compared to the results of neuropsychological assessment in patients with epilepsy: The influence of comorbid depression M Liik, L Vahter, K Gross-Paju, S Haldre Epilepsy research 84 (2-3), 194-200, 2009 | 54 | 2009 |
| Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial T Chitnis, B Banwell, L Kappos, DL Arnold, K Gücüyener, K Deiva, ... The Lancet Neurology 20 (12), 1001-1011, 2021 | 53 | 2021 |
| The prevalence of hereditary spastic paraplegia and the occurrence of SPG4 mutations in Estonia M Braschinsky, SM Lüüs, K Gross-Paju, S Haldre Neuroepidemiology 32 (2), 89-93, 2009 | 46 | 2009 |
| Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study A Bar-Or, H Wiendl, X Montalban, E Alvarez, M Davydovskaya, ... Multiple Sclerosis Journal 28 (6), 910-924, 2022 | 36 | 2022 |
| One question as a screening instrument for depression in people with multiple sclerosis L Vahter, M Kreegipuu, T Talvik, K Gross-Paju Clinical Rehabilitation 21 (5), 460-464, 2007 | 34 | 2007 |
| Conservative bladder management in advanced multiple sclerosis D De Ridder, D Ost, F Van der Aa, M Stagnaro, C Beneton, K Gross-Paju, ... Multiple Sclerosis Journal 11 (6), 694-699, 2005 | 33 | 2005 |
| Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial MB Roaldsen, A Eltoft, T Wilsgaard, H Christensen, ST Engelter, ... The Lancet Neurology 22 (2), 117-126, 2023 | 32 | 2023 |
| Bladder dysfunction in hereditary spastic paraplegia: what to expect? M Braschinsky, I Zopp, M Kals, S Haldre, K Gross-Paju Journal of Neurology, Neurosurgery & Psychiatry 81 (3), 263-266, 2010 | 29 | 2010 |
| Functional assessment of lower extremities in hereditary spastic paraplegia M Braschinsky, K Parts, H Maamägi, K Gross-Paju, S Haldre Archives of physical medicine and rehabilitation 90 (11), 1887-1890, 2009 | 26 | 2009 |
| Cognitive dysfunction during anti-NMDA-receptor encephalitis is present in early phase of the disease L Vahter, K Kannel, U Sorro, H Jaakmees, T Talvik, K Gross-Paju Oxford Medical Case Reports 2014 (4), 74-76, 2014 | 25 | 2014 |
